



COST BENEFIT ANALYSIS FOR BCKDK DEFICIENCY

Megan McCrillis, MPH

Policy Analyst, WA State Newborn Screening Program

John D. Thompson, PhD, MPA, MPH

Director, Newborn Screening Program



The criterion

5. Cost-benefit/Cost-effectiveness: The outcomes outweigh the costs of screening. All outcomes, both positive and negative, need to be considered in the analysis. Important considerations to be included in economic analyses include:

- The prevalence of the condition among newborns.
- The positive and negative predictive values of the screening and diagnostic tests.
- Variability of clinical presentation by those who have the condition.
- The impact of ambiguous results. For example the emotional and economic impact on the family and medical system.
- Adverse effects or unintended consequences of screening.

The cost- benefit model

- Decision Tree
 - Compares status quo v. screening model
- Data from:
 - Primary literature
 - States currently screening or pilot studies
 - Expert opinion
- Sensitivity analysis – vary assumptions
 - High and low estimates for parameters

The cost- benefit model


- Decision Tree
 - Compares status quo v. screening model
- Data from:
 - Primary literature → extremely limited
 - States currently screening or pilot studies → none
 - Expert opinion → mostly not accessible
- Sensitivity analysis – vary assumptions
 - High and low estimates for parameters

The cost- benefit model


- Consult:

- Anna Hidle, Public Health Economist, Washington Department of Health


The cost- benefit model



Status quo: No screening model



Newborn screening model



Benefits and Costs

No screening		
# babies with autism		#VALUE!
# babies without autism		#VALUE!
Universal screening		
# babies with autism		#VALUE!
# babies without autism		#VALUE!
SHIFT		
Cases of autism avoided		#VALUE!
BENEFITS		
Cost of autism care from birth to 18	\$106,388.79	Totals
Less tx costs (Total benefits)		#VALUE!
COSTS		
Cost of NBS per baby	?	Totals
Total cost NBS		#VALUE!
Cost per baby dx testing (branched chain)	\$2,270.00	
Cost of false(+) dx testing		#VALUE!
Total costs		#VALUE!
Benefit/Cost ratio		#VALUE!
Net benefit		#VALUE!

Summary

- The quality of the results are only as good as the data in the model
- We did not provide a cost-benefit ratio to the NBS Technical Advisory Committee
- The model is built
 - Parameters for missing assumptions could be entered in the future when data is available



Questions?